These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 33618904)

  • 21. Identification of risk epitope mismatches associated with de novo donor-specific HLA antibody development in cardiothoracic transplantation.
    McCaughan JA; Battle RK; Singh SKS; Tikkanen JM; Moayedi Y; Ross HJ; Singer LG; Keshavjee S; Tinckam KJ
    Am J Transplant; 2018 Dec; 18(12):2924-2933. PubMed ID: 29847022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HLA class II Eplet mismatch predicts De Novo DSA formation post lung transplant.
    Walton DC; Cantwell L; Hiho S; Ta J; Wright S; Sullivan LC; Snell GI; Westall GP
    Transpl Immunol; 2018 Dec; 51():73-75. PubMed ID: 30321645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Degree of HLA class II eplet mismatch load improves prediction of antibody-mediated rejection in living donor kidney transplantation.
    Tafulo S; Malheiro J; Santos S; Dias L; Almeida M; Martins S; Pedroso S; Mendes C; Lobato L; Castro-Henriques A
    Hum Immunol; 2019 Dec; 80(12):966-975. PubMed ID: 31604581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies.
    Steggerda JA; Kim IK; Haas M; Zhang X; Kang A; Pizzo H; Kamil E; Jordan S; Puliyanda D
    Pediatr Transplant; 2017 Dec; 21(8):. PubMed ID: 29159992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients.
    Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F
    Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor/Recipient HLA Molecular Mismatch Scores Predict Primary Humoral and Cellular Alloimmunity in Kidney Transplantation.
    Meneghini M; Crespo E; Niemann M; Torija A; Lloberas N; Pernin V; Fontova P; Melilli E; Favà A; Montero N; Manonelles A; Cruzado JM; Palou E; Martorell J; Grinyó JM; Bestard O
    Front Immunol; 2020; 11():623276. PubMed ID: 33776988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies.
    Parajuli S; Aziz F; Blazel J; Muth BL; Garg N; Mohamed M; Rice J; Mezrich JD; Hidalgo LG; Mandelbrot D
    Transplantation; 2021 Jul; 105(7):1548-1555. PubMed ID: 32732618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Comparison of HLA Molecular Mismatch Methods to Determine HLA Immunogenicity.
    Wiebe C; Kosmoliaptsis V; Pochinco D; Taylor CJ; Nickerson P
    Transplantation; 2018 Aug; 102(8):1338-1343. PubMed ID: 29443827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HLA B eplet mismatches in the context of delayed graft function and low tacrolimus trough levels are risk factors influencing the generation of de novo donor-specific antibodies and acute rejection in the early stage after kidney transplantation.
    Gao S; Gong H; Li M; Lan P; Zhang M; Kuang P; Zhang Y; Hu X; Ding C; Li Y; Ding X; Xue W; Zheng J
    Transpl Immunol; 2023 Dec; 81():101955. PubMed ID: 37931666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.
    Lachmann N; Niemann M; Reinke P; Budde K; Schmidt D; Halleck F; Pruß A; Schönemann C; Spierings E; Staeck O
    Am J Transplant; 2017 Dec; 17(12):3076-3086. PubMed ID: 28613392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients.
    Wan SS; Chadban SJ; Watson N; Wyburn K
    Am J Transplant; 2020 May; 20(5):1351-1364. PubMed ID: 31867849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IgG3 donor-specific antibodies with a proinflammatory glycosylation profile may be associated with the risk of antibody-mediated rejection after kidney transplantation.
    Pernin V; Bec N; Beyze A; Bourgeois A; Szwarc I; Champion C; Chauvin A; Rene C; Mourad G; Merville P; Visentin J; Perrochia H; Couzi L; Larroque C; Le Quintrec M
    Am J Transplant; 2022 Mar; 22(3):865-875. PubMed ID: 34863025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of HLA molecular level mismatching in ethnically diverse kidney transplant recipients receiving a steroid-sparing immunosuppression protocol.
    Santos E; Spensley K; Gunby N; Worthington J; Roufosse C; Anand A; Willicombe M
    Am J Transplant; 2024 Jul; 24(7):1218-1232. PubMed ID: 38403189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
    Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
    Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor selection in pediatric kidney transplantation using DR and DQ eplet mismatching: A new histocompatibility paradigm.
    Bryan CF; Chadha V; Warady BA
    Pediatr Transplant; 2016 Nov; 20(7):926-930. PubMed ID: 27448994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
    Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
    Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients.
    Zhang X; Kransdorf E; Levine R; Patel JK; Kobashigawa JA
    Hum Immunol; 2020 Jul; 81(7):330-336. PubMed ID: 32307126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On the clinical relevance of using complete high-resolution HLA typing for an accurate interpretation of posttransplant immune-mediated graft outcomes.
    Meneghini M; Perona A; Crespo E; Bemelman F; Reinke P; Viklicky O; Giral M; Palou E; Torija A; Donadeu L; Melilli E; Zuñiga J; Sefrin A; Lachmann N; Hu L; Hruba P; Guillot-Gueguen C; Brouard S; Grinyo J; Bestard O
    Front Immunol; 2022; 13():924825. PubMed ID: 36248818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study.
    Everly MJ; Briley KP; Haisch CE; Dieplinger G; Bolin P; Kendrick SA; Morgan C; Maldonado AQ; Rebellato LM
    Transpl Int; 2017 Jun; 30(6):566-578. PubMed ID: 28211192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.